Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Authors' reply re: The vaginal metabolome and microbiota of cervical HPV-positive and HPV-negative women: a cross-sectional analysis.

Borgogna JC, Shardell MD, Santori EK, Nelson TM, Rath JM, Glover ED, Ravel J, Gravitt P, Yeoman CJ, Brotman RM.

BJOG. 2020 Mar 10. doi: 10.1111/1471-0528.16148. [Epub ahead of print] No abstract available.

PMID:
32154972
2.

The vaginal metabolome and microbiota of cervical HPV-positive and HPV-negative women: a cross-sectional analysis.

Borgogna JC, Shardell MD, Santori EK, Nelson TM, Rath JM, Glover ED, Ravel J, Gravitt PE, Yeoman CJ, Brotman RM.

BJOG. 2020 Jan;127(2):182-192. doi: 10.1111/1471-0528.15981. Epub 2019 Nov 20.

PMID:
31749298
3.

Higher Levels of a Cytotoxic Protein, Vaginolysin, in Lactobacillus-Deficient Community State Types at the Vaginal Mucosa.

Nowak RG, Randis TM, Desai P, He X, Robinson CK, Rath JM, Glover ED, Ratner AJ, Ravel J, Brotman RM.

Sex Transm Dis. 2018 Apr;45(4):e14-e17. doi: 10.1097/OLQ.0000000000000774.

4.

Cigarette smoking is associated with an altered vaginal tract metabolomic profile.

Nelson TM, Borgogna JC, Michalek RD, Roberts DW, Rath JM, Glover ED, Ravel J, Shardell MD, Yeoman CJ, Brotman RM.

Sci Rep. 2018 Jan 16;8(1):852. doi: 10.1038/s41598-017-14943-3.

5.

Validation of the Glover-Nilsson Smoking Behavioral Questionnaire for the Portuguese population: a psychometric process.

Rocha V, Guerra MP, Lemos MS, Glover ED.

Am J Health Behav. 2014 Nov;38(6):801-6. doi: 10.5993/AJHB.38.6.1.

PMID:
25207505
6.

Association between cigarette smoking and the vaginal microbiota: a pilot study.

Brotman RM, He X, Gajer P, Fadrosh D, Sharma E, Mongodin EF, Ravel J, Glover ED, Rath JM.

BMC Infect Dis. 2014 Aug 28;14:471. doi: 10.1186/1471-2334-14-471.

7.

A comparison of three smokeless tobacco dependence measures.

Ebbert JO, Severson HH, Danaher BG, Schroeder DR, Glover ED.

Addict Behav. 2012 Nov;37(11):1271-7. doi: 10.1016/j.addbeh.2012.06.011. Epub 2012 Jun 21.

8.

Selegiline transdermal system (STS) as an aid for smoking cessation.

Kahn R, Gorgon L, Jones K, McSherry F, Glover ED, Anthenelli RM, Jackson T, Williams J, Murtaugh C, Montoya I, Yu E, Elkashef A.

Nicotine Tob Res. 2012 Mar;14(3):377-82. doi: 10.1093/ntr/ntr143. Epub 2011 Aug 16.

9.

Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic.

Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, Oncken CA, Tashkin DP, Reus VI, Akhavain RC, Fahim RE, Kessler PD, Niknian M, Kalnik MW, Rennard SI.

Clin Pharmacol Ther. 2011 Mar;89(3):392-9. doi: 10.1038/clpt.2010.317. Epub 2011 Jan 26.

10.

Formation and early history of the American Academy of Health Behavior.

McDermott RJ, Glover ED.

Am J Health Behav. 2010 Sep-Oct;34(5):563-72.

PMID:
20524886
11.

A multicenter phase 3 trial of lobeline sulfate for smoking cessation.

Glover ED, Rath JM, Sharma E, Glover PN, Laflin M, Tonnesen P, Repsher L, Quiring J.

Am J Health Behav. 2010 Jan-Feb;34(1):101-9.

PMID:
19663757
12.

Predictors of smokeless tobacco abstinence.

Ebbert JO, Glover ED, Shinozaki E, Schroeder DR, Dale LC.

Am J Health Behav. 2008 Nov-Dec;32(6):735-40. doi: 10.5555/ajhb.2008.32.6.735.

13.

Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis.

Nides M, Glover ED, Reus VI, Christen AG, Make BJ, Billing CB Jr, Williams KE.

Am J Health Behav. 2008 Nov-Dec;32(6):664-75. doi: 10.5555/ajhb.2008.32.6.664.

PMID:
18442345
14.

Hepatic transcriptional networks induced by exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Hayes KR, Zastrow GM, Nukaya M, Pande K, Glover E, Maufort JP, Liss AL, Liu Y, Moran SM, Vollrath AL, Bradfield CA.

Chem Res Toxicol. 2007 Nov;20(11):1573-81. Epub 2007 Oct 20.

15.

Are instructions for over-the-counter nicotine replacement therapy products readable?

Stevens AB, McDaniel KS, Glover ED, Wallace LS.

Am J Health Behav. 2007 Sep-Oct;31 Suppl 1:S79-84.

PMID:
17931140
16.

Varenicline: progress in smoking cessation treatment.

Glover ED, Rath JM.

Expert Opin Pharmacother. 2007 Aug;8(11):1757-67. Review.

PMID:
17685891
17.

A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers.

Glover ED, Laflin MT, Schuh KJ, Schuh LM, Nides M, Christen AG, Glover PN, Strnad JV.

Addiction. 2007 May;102(5):795-802.

PMID:
17506156
18.

Sensitivity and specificity of a reagent-impregnated test strip in identifying smokeless tobacco users.

Glover ED, Glover PN, Laflin MT, Nochur SV, Strnad JV.

Nicotine Tob Res. 2007 Apr;9(4):499-503.

PMID:
17454705
19.

Bupropion SR for the treatment of smokeless tobacco use.

Dale LC, Ebbert JO, Glover ED, Croghan IT, Schroeder DR, Severson HH, Hurt RD.

Drug Alcohol Depend. 2007 Sep 6;90(1):56-63. Epub 2007 Mar 13.

20.

2,3,7,8-Tetrachlorodibenzo-p-dioxin induces premature activation of the KLF2 regulon during thymocyte development.

McMillan BJ, McMillan SN, Glover E, Bradfield CA.

J Biol Chem. 2007 Apr 27;282(17):12590-7. Epub 2007 Mar 2.

21.

Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial.

Rennard SI, Glover ED, Leischow S, Daughton DM, Glover PN, Muramoto M, Franzon M, Danielsson T, Landfeldt B, Westin A.

Nicotine Tob Res. 2006 Aug;8(4):555-64.

PMID:
16920653
22.

Publication ethics: an examination of authorship practices.

Laflin MT, Glover ED, McDermott RJ.

Am J Health Behav. 2005 Nov-Dec;29(6):579-87.

PMID:
16336112
23.

Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving.

Niaura R, Sayette M, Shiffman S, Glover ED, Nides M, Shelanski M, Shadel W, Koslo R, Robbins B, Sorrentino J.

Addiction. 2005 Nov;100(11):1720-30.

PMID:
16277632
24.

Developmental history of the Glover-Nilsson smoking behavioral questionnaire.

Glover ED, Nilsson F, Westin A, Glover PN, Laflin MT, Persson B.

Am J Health Behav. 2005 Sep-Oct;29(5):443-55.

PMID:
16201861
25.

ViewPoint: conversation with Elbert D. Glover. Interview by Molly T. Laflin and David R. Black.

Glover ED.

Am J Health Behav. 2003 Nov-Dec;27(6):657-69. No abstract available.

PMID:
14672396
26.

Treating nicotine dependence.

Glover ED, Glover PN, Payne TJ.

Am J Med Sci. 2003 Oct;326(4):183-6. Review.

PMID:
14557731
27.

A comparison of a nicotine sublingual tablet and placebo for smoking cessation.

Glover ED, Glover PN, Franzon M, Sullivan CR, Cerullo CC, Howell RM, Keyes GG, Nilsson F, Hobbs GR.

Nicotine Tob Res. 2002 Nov;4(4):441-50.

PMID:
12521403
28.

A comparison of sustained-release bupropion and placebo for smokeless tobacco cessation.

Glover ED, Glover PN, Sullivan CR, Cerullo CL, Hobbs G.

Am J Health Behav. 2002 Sep-Oct;26(5):386-93.

PMID:
12206448
29.

Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation.

Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh-Geiss J.

Nicotine Tob Res. 2001 May;3(2):131-40.

PMID:
11403727
30.

Bupropion for smoking cessation : predictors of successful outcome.

Dale LC, Glover ED, Sachs DP, Schroeder DR, Offord KP, Croghan IT, Hurt RD.

Chest. 2001 May;119(5):1357-64.

PMID:
11348939
31.

Pharmacologic treatments for the nicotine dependent smoker.

Glover ED, Glover PN.

Am J Health Behav. 2001 May-Jun;25(3):179-82. Review.

PMID:
11322615
32.

2000 Research Laureate Medallion Award.

Glover ED.

Am J Health Behav. 2001 May-Jun;25(3):163-4. No abstract available.

PMID:
11322613
33.

Treating nicotine dependence.

Glover ED, Glover PN.

W V Med J. 2001 Jan-Feb;97(1):39-43.

PMID:
11257836
34.

Correlates of youth smokeless tobacco use.

Goebel LJ, Crespo RD, Abraham RT, Masho SW, Glover ED.

Nicotine Tob Res. 2000 Nov;2(4):319-25.

PMID:
11197311
35.

Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism.

Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, Glover ED, Sachs DP, Hurt RD.

Br J Psychiatry. 1999 Feb;174:173-8.

PMID:
10211174
36.

The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day.

Daughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E, Repsher L, Millatmal T, Killen JD, Nowak RT, Ullrich F, Patil KD, Rennard SI.

Prev Med. 1999 Feb;28(2):113-8.

PMID:
10048102
37.

A comparison of sustained-release bupropion and placebo for smoking cessation.

Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM.

N Engl J Med. 1997 Oct 23;337(17):1195-202.

38.

Smoking Cessation Strategies.

Glover ED.

Am J Ther. 1996 May;3(5):358-363. No abstract available.

PMID:
11862272
39.

OTC nicotine gum.

Glover ED.

J Fam Pract. 1995 Jan;40(1):15-6; author reply 16-7. No abstract available.

PMID:
7807028
40.
41.

Transdermal nicotine patch for smoking cessation.

Glover ED.

N Engl J Med. 1992 Jan 30;326(5):344; author reply 345. No abstract available.

PMID:
1728741
42.

Study indicates smoking cessation improves workplace absenteeism rate.

Jackson SE, Cheneweth D, Glover ED, Holbert D, White D.

Occup Health Saf. 1989 Dec;58(13):13, 15-6, 18. No abstract available.

PMID:
2601927
43.

Smokers and smokeless tobacco users: a comparison of personality characteristics among collegiate males.

Glover ED, Edmundson EW, White DM.

Health Educ. 1989 Dec;20(7):37-40. No abstract available.

PMID:
2516072
44.

Smokeless tobacco use among American college students.

Glover ED, Laflin M, Flannery D, Albritton DL.

J Am Coll Health. 1989 Sep;38(2):81-5.

PMID:
2789245
45.

Relapse prevention: implications for health promotion professionals.

Rose-Colley M, Eddy JM, Glover ED.

Health Values. 1989 Sep-Oct;13(5):8-13.

PMID:
10296324
46.

Smokeless tobacco use by youth in the U.S.

Boyd GM, Glover ED.

J Sch Health. 1989 May;59(5):189-94.

PMID:
2739361
47.
48.

Breaking the barriers: strategies for a comprehensive u.s. Tobacco control program.

Glover ED, Albritton DL, Mansfield C.

Int Q Community Health Educ. 1989 Jan 1;10(3):223-39. doi: 10.2190/LT3U-CRD7-N30D-VWT8.

PMID:
20840932
49.

An interpretative review of smokeless tobacco research in the United States: Part II.

Glover ED, Schroeder KL, Henningfield JE, Severson HH, Christen AG.

J Drug Educ. 1989;19(1):1-19. Review.

PMID:
2656965
50.

Anti-smoking programs need to incorporate smokeless tobacco education.

Glover ED.

J Sch Health. 1988 Sep;58(7):266. No abstract available.

PMID:
3172718

Supplemental Content

Loading ...
Support Center